Reviving Polymyxins: Achievements, Lessons and the Road Ahead

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Antibiotic resistance poses a significant global health threat, with Gram-negative 'superbugs' like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae presenting a critical challenge.
• Polymyxins are vital last-resort antibiotics for treating infections caused by these multidrug-resistant Gram-negative bacteria.
• Historical limitations in pharmacological and clinical data have hindered the optimal use of polymyxins.

Purpose of the Study:

• To provide a comprehensive overview of the progress in polymyxin research over the past two decades.
• To consolidate knowledge on polymyxin chemistry, microbiology, pharmacology, clinical applications, and drug discovery.
• To highlight future directions for improving the clinical utility of polymyxins.

Main Methods:

• Comprehensive literature review of polymyxin research from the last 20 years.
• Analysis of recent pharmacological findings and their impact on clinical practice.
• Synthesis of information on new-generation polymyxin development.

Main Results:

• Significant advancements have been made in understanding polymyxin chemistry, microbiology, and pharmacology.
• Recent pharmacological data have enabled the development of the first evidence-based polymyxin dosing recommendations.
• Progress in drug discovery has led to the identification of new-generation polymyxins.

Conclusions:

• The review consolidates recent progress, addressing historical knowledge gaps in polymyxin use.
• Scientifically-based dosing and new polymyxin discoveries offer improved therapeutic options.
• Future research should focus on overcoming challenges to enhance the clinical effectiveness of these critical last-line antibiotics.